Q1 2026 Karyopharm Therapeutics Inc Earnings Call Transcript

May 14, 2026 / 12:00 PM GMT

Release Date Price: $8.9 (+0.56%)

Transcript 10-Q8-K

Key Points

Positve

Karyopharm Therapeutics Inc (KPTI) reported strong net product revenue growth, driven by favorable gross-to-net dynamics.
The Phase III SENTRY trial in myelofibrosis showed a compelling profile for selinexor in combination with ruxolitinib, including rapid, deep, and sustained spleen volume responses.
The company completed enrollment in the export EC042 trial for endometrial cancer, with top-line data expected in mid-2026.
Karyopharm Therapeutics Inc (KPTI) strengthened its balance sheet with financing completed in Q1, providing increased liquidity.
The company has established strong commercial capabilities and relationships, positioning it well for future potential launches in myelofibrosis and endometrial cancer.

Negative

Underlying demand for XPOVIO was lower compared to the first quarter of 2025 due to new competitive entrants.
The company faces challenges in the evolving and competitive landscape of multiple myeloma treatment.
There is uncertainty regarding the timing and outcome of FDA engagements and potential SNDA for myelofibrosis.
The company reported a net loss of $22.4 million for the quarter, although this was an improvement from the previous year.
The Phase III SENTRY trial did not achieve statistical significance for symptom improvement at week 24, although both arms showed similar improvements from baseline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

KPTI.OQ - Karyopharm Therapeutics Inc
Q1 2026 Karyopharm Therapeutics Inc Earnings Call
May 14, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everybody. My name is Kelsey, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics First Quarter 2026 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Mr. Brennan Strong, Senior Vice President, Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning, and thank you all for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.